NOVELIX PHARMACEUTICALS LIMITED — Peer Comparison

How the peer fair value is calculated and which companies were used as benchmarks.

Base peer fair value

₹28.19

Bear uses each eligible multiple’s 25th percentile; Base retains the current production median; Bull uses the 75th percentile. Quartiles interpolate between sorted observations at (n − 1) × percentile. Each peer has equal weight within a method. These are distribution scenarios, not confidence intervals or scenario probabilities.

Selected peers and raw cached multiples
Peer	P/E	P/B	EV/EBITDA	P/S
SHUKRAPHAR	50.52	33.68	—	—
KRSNAA	18.03	1.84	8.57	2.29
NGLFINE	44.10	6.45	22.74	3.48
SHALBY	14.78	1.51	—	—
JAGSNPHARM	36.45	5.58	26.07	5.45
AMRUTANJAN	24.54	3.84	19.79	2.99
SYNCOMF	16.58	4.49	—	—
GKSL	54.69	4.25	44.85	15.44

The current peer engine’s selected industry/sector peers and cached multiples are preserved. Subject multiples use the engine’s existing EOD-price scaling. Peer observations may have different refresh dates; these scenarios do not claim synchronized market data.

P/E · 58.33% effective method weight

Company multiple: 60.5000×. Eligible peers (8): SHUKRAPHAR 50.5200×; KRSNAA 18.0300×; NGLFINE 44.1000×; SHALBY 14.7800×; JAGSNPHARM 36.4500×; AMRUTANJAN 24.5400×; SYNCOMF 16.5800×; GKSL 54.6900×.

Scenario	Peer multiple	Implied fair value
Bear (P25)	17.6675×	₹22.46
Base (median)	30.4950×	₹38.76
Bull (P75)	45.7050×	₹58.09

P/B · 41.67% effective method weight

Company multiple: 24.4000×. Eligible peers (7): KRSNAA 1.8400×; NGLFINE 6.4500×; SHALBY 1.5100×; JAGSNPHARM 5.5800×; AMRUTANJAN 3.8400×; SYNCOMF 4.4900×; GKSL 4.2500×.

Scenario	Peer multiple	Implied fair value
Bear (P25)	2.8400×	₹8.95
Base (median)	4.2500×	₹13.39
Bull (P75)	5.0350×	₹15.87

Fair value = the production method’s median fair value × scenario multiple ÷ median multiple, equivalent to the current engine’s price × peer multiple ÷ subject multiple. Effective method weights are normalized across methods with a fair value; the final peer result is rounded to two decimals.

Only methods eligible under the current sector/company rules contribute. Subject multiples must be positive. Peer observations must pass the existing method-specific bounds and sector caps. Four eligible peers per contributing method are required for quartiles; the production median's existing minimum is unchanged. A missing method's Bear/Bull is not replaced with another method or a Base estimate.

EV/EBITDA does not contribute: the subject multiple/fair value is unavailable. Its production peer median is 22.74×.

Final peer scenario values
Bear	Base	Bull
₹16.83	₹28.19	₹40.50

Peer selection

Peers are selected from the same Healthcare industry. 8 companies were matched as valid comparables.

Same-industry peers share similar business models, cost structures, and growth prospects — making them the most appropriate benchmarks for valuation multiples.

Peer comparison table

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
NOVELIX PHARMACEUTICALS LIMITED NOVELIX · you	₹184 Cr	60.5×	24.4×	—	40.4%	0.0%	—
Sector median	—	30.5×	4.3×	22.7×	15.1%	10.6%	13.2%
Shukra Pharmaceuticals Limited SHUKRAPHAR	₹1,821 Cr	50.5×	33.7×	—	66.4%	0.6%	—
Krsnaa Diagnostics Limited KRSNAA	₹1,771 Cr	18.0×	1.8×	8.6×	10.3%	13.1%	16.6%
NGL Fine-Chem Limited NGLFINE	₹1,744 Cr	44.1×	6.5×	22.7×	14.6%	9.6%	21.7%
Shalby Limited SHALBY	₹1,658 Cr	14.8×	1.5×	—	10.2%	0.1%	—
Jagsonpal Pharmaceuticals Limited JAGSNPHARM	₹1,566 Cr	36.5×	5.6×	26.1×	15.6%	15.0%	6.7%
Amrutanjan Health Care Limited AMRUTANJAN	₹1,502 Cr	24.5×	3.8×	19.8×	15.6%	11.5%	9.8%
Syncom Formulations (India) Limited SYNCOMF	₹1,402 Cr	16.6×	4.5×	—	27.2%	0.2%	—
Gujarat Kidney And Super Speciality Limited GKSL	₹1,266 Cr	54.7×	4.3×	44.8×	6.1%	18.9%	—

Peer comparison verdict

NOVELIX trades at a premium to peers (P/E 60.5× vs median 30.5×), but its higher ROE of 40.4% (sector 15.1%) justifies much of that premium — quality rarely comes cheap.

Why median? Why these weights?

Median over mean: The sector median is used instead of the average because valuation multiples have extreme outliers — one high-growth company at 200× P/E would dramatically skew a mean. The median gives the middle value in the peer set, which better represents typical pricing.

Sector-specific weights: The weight given to each method reflects what matters most in this sector. For banks, P/B dominates because their value is tied to book assets. For IT companies, P/E carries the most weight because earnings quality matters more than asset base. For capital-intensive businesses, EV/EBITDA accounts for varying debt levels across peers and removes financing structure bias.

Limitations of peer comparison

Peer comparison assumes comparable companies are truly comparable — which is never perfectly true. Sector classifications can be imperfect: a conglomerate classified as "IT" may also have significant manufacturing revenue. Small peer counts (below 5) reduce confidence, as a single outlier can skew the sector median. When the entire sector is broadly expensive, peer comparison will show even an expensive stock as "fairly valued" relative to its peers.

The peer fair value shown is an algorithmic estimate based on publicly available financial data. It is not investment advice or a recommendation to buy, sell, or hold any security. Please consult a SEBI-registered investment adviser before making any investment decision.